- ANGLE has been granted a Canadian patent for its Parsortix system, which captures rare cells in blood for medical analysis.

The granted Canadian patent provides protection over a wide range of uses of the Parsortix technology. Granted patents have already been secured in the United States, China and Australia. Corresponding patent applications have been made worldwide in countries considered to represent substantial markets for Parsortix products. The company is pursuing a strategy to strengthen the breadth and duration of its patent coverage across major markets worldwide to maximise the commercial returns that can be achieved from its Parsortix technology. New patent applications will continue to be made in all territories consistent with this strategy.

ANGLE founder and chief executive, Andrew Newland, commented: "The grant of this patent in Canada further strengthens ANGLE's IP position and maintains our momentum in expanding patent coverage across major markets worldwide."

At 9:18am: [LON:AGL] Angle PLC share price was +2p at 85p

Story provided by